Spotlight on... A look at pharma's many TV spokes-creatures; Ferring taps Karolinska for microbiome R&D; Unum settles into new Cambridge HQ; and more...

Over the past decade, pharma companies have increasingly relied on animated characters to advertise their products, using cute, quaint or questionable creatures to illustrate how drugs work. FiercePharmaMarketing took a look at some of the most memorable spokes-things in recent history. More

@FierceBiotech: Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: $MNKD call on Feb. 3 gives investors a chance to ask a few questions. Release | Follow @JohnCFierce

> Ferring Pharmaceuticals is collaborating with Sweden's Karolinska Institutet to establish a microbiomics-focused research center. News

> Sen. Bernie Sanders has pledged to block the approval of Robert Califf, nominated by President Barack Obama to be the next FDA commissioner. Story

> Unum Therapeutics moved into a new headquarters in Cambridge, MA, planning to grow its staff to roughly 80 employees as it pushes forward with immunotherapies for cancer. More

Medical Device News

@FierceMedDev: J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. Story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. ICYMI from FiercePharma | Follow @EmilyWFierce

> Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article

> Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. More

> Illumina finds match in Australian genomics company for transplant sequencing work. Report

Pharma News

@FiercePharma: India and France committed to restart trade talks stalled on GVK row. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: J&J's new launches deliver, but overall sales fall short on hep C, strong dollar. Article | Follow @CarlyHFierce

> Gilead faces legal action in Massachusetts if it doesn't cut hep C prices: State AG. Story

> Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig. Article

Biotech Research News

> Researchers have isolated human monoclonal antibodies that target multiple strains of Ebola. Story

> Science team says they've taken another step toward a potential cure for diabetes. More

> UT Southwestern team says new liver cancer therapy shows promise in mice. Report

> New molecule targets cancer stem cells. Item

> UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. Article

Vaccines News

> Takeda's Hib vaccine gets Japanese approval. More

> Case Western, Merck team spotlights vaccine response predictors. Report

> U.K., Gates pledge $4.3 billion to take malaria fight beyond vax. Story

> U.K. committee warns the country is unprepared for an epidemic. Item

> Zika outbreak triggers R&D attention from pharma, governments. Article

Pharma Marketing News

> Time to tap YouTube for talent? Cold remedy Zicam goes there in deal with singer Tyler Ward. More

> New brands, stepped-up spending drive big TV-ad outlay for diabetes in 2015. Story

> What do docs want? Face-to-face tablet meetings with reps. More

> Massachusetts AG threatens legal action against Gilead over pricey hep C meds. Item

> Shire's back on track with its dry-eye threat to Allergan's Restasis. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.